Linkedin Facebook Twitter Youtube

08 Aug EG427

Posted at 16:48h in by

Philippe Chambon, M.D., Ph.D., CEO

Oct. 12 | 11:15pm | Ecolab Life Sciences Ballroom 

Paris, France

(Private)

EG427 is unlocking the full potential of gene therapy for the treatment of localized severe chronic diseases. Our proprietary platform of non-replicative herpes-based vectors is uniquely able to modulate the activity of various neurons subtypes. With an IND slated for early 2024, we will be the next company, to have a non-replicative herpes-based construct in human clinical trial, and the first one to address sensory neuron-based pathologies. Our first product targets a broad range of conditions linked to bladder dysfunction originating from its sensory innervation, starting with a human POC in neurogenic bladder post Spinal Cord Injury.

www.eg427.com



About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 7-9, 2024
Arizona Biltmore
Phoenix, AZ

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions